Glasdegib is under clinical development by Pfizer and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase III drugs for Chronic Myelomonocytic Leukemia (CMML) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Glasdegib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glasdegib (Daurismo) is a anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients aged 75 years and older or who have comorbidities that preclude use of intensive induction chemotherapy.
Glasdegib (PF-04449913) is under development for the treatment of chronic myelomonocytic leukemia, graft versus host disease, and glioblastoma. The drug candidate is administered orally as a tablet. It was also under development for the treatment of hematological malignancies including primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia-myelofibrosis (PET-MF), solid tumor, and myelodysplastic syndrome.
Glasdegib was under development for the treatment of newly diagnosed acute myelocytic leukemia.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Glasdegib’s drug-specific PTSR and LoA scores, buy the report here.